Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Mersana Therapeutics, Inc. (MRSN : NSDQ)

• Company Description    Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $28.93 Daily Weekly Monthly 20 Day Moving Average: 74,576 shares Shares Outstanding: 5.00 (millions) Market Capitalization: $144.61 (millions) Beta: 0.44 52 Week High: $36.38 52 Week Low: $5.21 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 5.31% 5.49% 12 Week 218.96% 213.82% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 840 MEMORIAL DRIVE - CAMBRIDGE,MA 02139 USA ph: 617-498-0020 fax: - mersana@argotpartners.com http://www.mersana.com

• General Corporate Information    Officers Martin Huber - Chief Executive Officer and President David Mott - Chairman of the Board Brian DeSchuytner - Chief Operating Officer and Senior Vice President Ashish Mandelia - Vice President and Chief Accounting Officer Lawrence M. Alleva - Director Peer Information Mersana Therapeutics, Inc. (CORR.) Mersana Therapeutics, Inc. (RSPI) Mersana Therapeutics, Inc. (CGXP) Mersana Therapeutics, Inc. (BGEN) Mersana Therapeutics, Inc. (GTBP) Mersana Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 59045L205 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/02/26 Share - Related Items Shares Outstanding: 5.00 Most Recent Split Date: 7.00 (0.04:1) Beta: 0.44 Market Capitalization: $144.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-2.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.67 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/02/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 4.36 EPS Growth vs. Year Ago Period: 32.89% vs. Previous Quarter: 62.99% Sales Growth vs. Year Ago Period: -12.61% vs. Previous Quarter: 260.24% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - -65.42 06/30/25 - -54.85 Current Ratio 12/31/25 - - 09/30/25 - 1.39 06/30/25 - 1.35 Quick Ratio 12/31/25 - - 09/30/25 - 1.39 06/30/25 - 1.35 Operating Margin 12/31/25 - - 09/30/25 - -199.34 06/30/25 - -201.61 Net Margin 12/31/25 - - 09/30/25 - -211.21 06/30/25 - -212.94 Pre-Tax Margin 12/31/25 - - 09/30/25 - -211.21 06/30/25 - -211.74 Book Value 12/31/25 - - 09/30/25 - -11.93 06/30/25 - -10.65 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - -

Powered by Zacks Investment Research ©